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Genetics of Hypertrophic Cardiomyopathy
After 20 Years
Clinical Perspectives
Barry J. Maron, MD,* Martin S. Maron, MD,† Christopher Semsarian, MB, BS, PHD‡
Minneapolis, Minnesota; Boston, Massachusetts; and Sydney, New South Wales, Australia
Hypertrophic cardiomyopathy (HCM) is the most common familial heart disease with vast genetic heterogeneity,
demonstrated over the past 20 years. Mutations in 11 or more genes encoding proteins of the cardiac sarco-
mere (1,400 variants) are responsible for (or associated with) HCM. Explosive progress achieved in under-
standing the rapidly evolving science underlying HCM genomics has resulted in fee-for-service testing, making
genetic information widely available. The power of HCM mutational analysis, albeit a more limited role than ini-
tially envisioned, lies most prominently in screening family members at risk for developing disease and exclud-
ing unaffected relatives, which is information not achievable otherwise. Genetic testing also allows expansion of
the broad HCM disease spectrum and diagnosis of HCM phenocopies with different natural history and treat-
ment options, but is not a reliable strategy for predicting prognosis. Interfacing a heterogeneous disease such as
HCM with the vast genetic variability of the human genome, and high frequency of novel mutations, has created
unforeseen difficulties in translating complex science (and language) into the clinical arena. Indeed, proband
diagnostic testing is often expressed on a probabilistic scale, which is frequently incompatible with clinical deci-
sion making. Major challenges rest with making reliable distinctions between pathogenic mutations and benign
variants, and those judged to be of uncertain significance. Genotyping in HCM can be a powerful tool for family
screening and diagnosis. However, wider adoption and future success of genetic testing in the practicing cardio-
vascular community depends on a standardized approach to mutation interpretation, and bridging the communi-
cation gap between basic scientists and clinicians. (J Am Coll Cardiol 2012;60:705–15) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.068For over 50 years, hypertrophic cardiomyopathy (HCM)
has been recognized as a familial cardiac disease with highly
visible risk for sudden death and disease progression, char-
acterized by heterogeneous phenotypic expression, natural
history, and genetic profile (1–6). HCM is the most
common monogenic cardiovascular disease with a preva-
lence of 1:500 (7).
For HCM, the molecular era emerged more than 20 years
ago with identification of disease-causing mutations in
genes coding for proteins of the cardiac sarcomere (5,8,9).
These breakthrough observations defining the basic genetic
substrate were accompanied by considerable optimism and
expectation that mutational analysis would revolutionize
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2012, accepted February 3, 2012.HCM with regard to diagnosis and prediction of clinical
course, as well as guiding management (10–12).
More recently, striking scientific advances in molecular
genetics have resulted in availability of comprehensive
commercial genetic testing to the practicing cardiovascular
community, while paradoxically creating many unanswered
questions, and communication gaps surrounding translation
of genetic information to clinical decision making. Therefore,
it is timely to place the benefits and challenges of genotyping in
HCM into perspective, for a disease that epitomizes applica-
tion of genetic science to cardiovascular medicine.
Historical Perspectives
HCM is inherited in an autosomal dominant Mendelian
pattern with variable expressivity and age-related penetrance
(3–5,9,11,13). Offspring of an affected individual have a
50% probability of inheriting a mutation and risk for
disease; alternatively, sporadic cases may be due to de novo
mutations in the proband but absent from the parents.
For its first 25 years, diagnosis of HCM could only be
made through integration of examination, electrocardio-
gram, and invasive angiographic/hemodynamic studies, dis-
b
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tients with left ventricular (LV)
outflow obstruction (1) (Fig. 1).
In the early 1970s, echocardi-
ography afforded noninvasive vi-
sualization of left ventricular hy-
pertrophy (LVH), and reliable
identification of family members
with and without the HCM phe-
notype (14). Introducing basic
science to HCM, by interfacing
deoxyribonucleic acid (DNA)–
based methodologies and classi-
cal segregation linkage analysis
with echocardiography, allowed mapping HCM to a caus-
ative locus on chromosome 14 in 1989 (8). In 1990,
sequence analysis of a candidate gene revealed a pathogenic
missense mutation in the beta-myosin heavy chain gene
(MYH7Arg 403 Gln) to be responsible for HCM (9).
Molecular Basis of HCM
The substrate, 2011. Two decades of intensive investiga-
tion have defined the vast and daunting heterogeneity of the
HCM substrate. The early report of 7 mutations in 1 gene
(MYH7) (10) has now expanded to 11 or more causative
genes (5,13,15–21) with 1,400 mutations (Dr. H. Rehm,
personal communication, August 2011), expressed primarily
or exclusively in the heart. These genes encode thick and thin
myofilament proteins of the sarcomere or contiguous Z-disc
(Table 1). Mutations in several additional sarcomere (or
calcium-handling) genes have been proposed, but with less
evidence supporting pathogenicity (Table 1). Of those
patients with positive genetic tests, about 70% are found to
have mutations (of either definite or uncertain pathogenic-
ity) in the 2 most common genes, MYH7 and myosin-
inding protein C (MBPC3), while other genes including
roponin T, troponin I, -tropomyosin, and -actin each
account for a small proportion of patients (1% to 5%).
Types of mutations. The vast majority (about 90%) of
pathogenic mutations altering physical and functional prop-
erties of proteins are missense, in which a single normal
amino acid is exchanged for another (e.g., replacement of
arginine for glutamine). Alternatively, more radical muta-
Abbreviations
and Acronyms
GINA  Genetic
Information Non-
Discrimination Act
HCM  hypertrophic
cardiomyopathy
LV  left ventricle/
left ventricular
LVH  left ventricular
hypertrophy
VUS  variant of uncertain
significance
Figure 1 HCM Landmarks
Genetic and clinical advances over the 50-year history of hypertrophic cardiomyotions affect many amino acids in the protein, resulting in a
very different product (i.e., frameshift), and are generally
predicted to trigger more substantial clinical consequences.
Frameshift mutations are caused by insertion or deletion of
1 nucleic acids in the coding region often resulting in
shortened truncated proteins (frequently found in the
MYBPC gene), or abnormal splicing of messenger ribonu-
cleic acid (mRNA).
Genetic Testing for HCM
Background. HCM genetic testing was initially confined
to the realm of a few research laboratories focused on
enhancing a basic understanding of this disease. Testing
results were unpredictable, as laboratories lacked sufficient
(HCM). ICD  implantable cardioverter-defibrillator; SD  sudden death.
Molecular Substrate of HCMTable 1 Molecular Substrate of HCM
Strongest evidence for pathogenicity
Thick filament
1. -myosin heavy chain MYH7
2. Regulatory myosin light chain MYL2
3. Essential myosin light chain MYL3
Thin filament
4. Cardiac troponin T TNNT2
5. Cardiac troponin I TNNI3
6. Cardiac troponin C TNNC1
7. -tropomyosin TPM1
8. -cardiac actin ACTC
Intermediate filament
9. Cardiac myosin-binding protein C MYBPC3
Z-disc
10. -actinin 2 ACTN2
11. Myozenin 2 MYOZ2
Lesser evidence for pathogenicity
Thick filament
12. -myosin heavy chain MYH6
13. Titin TTN
Z-disc
14. Muscle LIM protein CSRP3
15. Telethonin TCAP
16. Vinculin/metavinculin VCL
Calcium handling
17. Calsequestrin CASQ2
18. Junctophilin 2 JPH2
HCM  hypertrophic cardiomyopathy.pathy
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August 21, 2012:705–15 Genetics in Hypertrophic Cardiomyopathyresources to accommodate all clinical requests. In 2003,
genetic testing entered the mainstream of the healthcare
system with automated DNA sequencing providing rapid,
reliable, and comprehensive molecular diagnosis on a fee-
for-service basis. DNA testing typically requires transport-
ing 5 to 10 ml of whole blood to institutional or commercial
laboratories (Table 2), all offering similar panels, including
established HCM causative genes, phenocopies, and possi-
bly other genes with lesser evidence for pathogenicity. U.S.
proband testing may be associated with significant cost and
economic burden, but also with a variety of insurance and
billing strategies available.
Pathogenic versus nonpathogenic mutations. A mutation
can be considered pathogenic (or likely pathogenic) on the
basis of the preponderance of evidence from the following
criteria (15,22) (Table 3): 1) cosegregates with the HCM
phenotype (i.e., LV hypertrophy) in family members, i.e., the
only criterion that relies on data obtained directly from the
patients; 2) previously reported or identified as a cause of
HCM; 3) absent from unrelated and ethnic-matched normal
controls; 4) protein structure and function is importantly
altered (e.g., frameshift with truncation); and 5) amino acid
sequence change in a region of the protein otherwise highly
conserved through evolution with virtually no variation ob-
served among species, suggesting its importance to basic
cellular function.
On the other hand, many amino acid substitutions in DNA
sequence do not cause disease and are regarded as benign
polymorphisms (i.e., variants not generally expected to be
deleterious), by convention occurring in 0.5% to 1.0% of
ethnic-specific normal control populations. Nevertheless, the
relevance for causing disease attached to a significant minority
of such identified variants remains unclear, even after applying
all criteria for pathogenicity. As a result, these mutations are
assigned by genetic test reports into an ambiguous category
(i.e., variants of uncertain significance [VUS or VOUS])
(15,21,22) with virtually no clinical utility for family screening.
Indeed, distinguishing pathogenic mutations from VUS,
or rare nonpathogenic variants, has increasingly emerged as
a dilemma for interpreting testing results in HCM, and has
been regarded as the “Achilles heel” of this diagnostic
strategy (15). This issue has become particularly challenging
as the reduced cost of technology now allows comprehensive
DNA sequencing of the exome and even the whole genome
(23,24,25). Although affording scientific insights, this de-
velopment also substantially increases the recognition of
VUS, potentially creating only further ambiguity in test
reports. That VUS occur more commonly in human control
populations than previously appreciated (genetic variation
referred to collectively as “background noise”) underscores
the need for more definitive criteria to differentiate patho-
genic mutations from benign genetic “noise.”
Notably, generally accepted guidelines for interpreting VUS
are currently lacking, with estimated frequencies varying dra-
matically from 5% to 50%, largely dependent on the number of
pathogenicity classes used to categorize mutations and the Co T
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d
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ratory commercial testing strategies vary widely, employing
from 3 to 7 descriptive pathogenicity classes to construct
formal reports, thereby creating the distinct possibility that
different interpretations of pathogenicity may emanate from
different laboratories for the same mutation (Table 2).
Indeed, it is not universally appreciated in the clinical
cardiovascular community that molecular diagnosis and assign-
Current Criteria Used to Determine Probability for Pathogenicity ofTable 3 Current Criteria Used to Determine Probability for Path
Pathogenicity Criterion Description
Cosegregation Determine whether mutation is present
with LVH and absent in those without
Prior evidence of pathogenicity Documentation that mutation is HCM di
in 1 patient in published literature,
individual experience of a testing labo
Control population Confidence for pathogenicity increased w
absent from large, ethnicity-matched
healthy population
Major disruption protein structure,
and function
Mutant proteins are judged to have subs
altered physical properties
*Presented in approximate order of the power for establishing disease-causing status for a given m
screening the threshold burden of evidence for a gene already known to cause HCM is lower than
odds) score 3. ‡Databases proposed to systematically assemble genetic data from all clinica
assembled its own control group. §100 subjects (200 alleles) considered the minimum; contro
sequence, associated with insertions/deletions, or resulting in truncated (shortened) protein; 2) o
location in a functionally important site in genetic sequence leading to dysfunction. ¶Includes: 1) in
using extracted protein of various species; 3) predictive software program models.
HCM  hypertrophic cardiomyopathy; LVH  left ventricular hypertrophy.
Figure 2 Pathogenicity in Probands
Genetic testing interpretation categories are depicted with respect to the relative s
these test results occur. These variant classifications are those commonly used b
Benign and likely benign variants are not responsible for disease (polymorphisms)
of which are currently unresolved in terms of disease pathogenesis or causation.
nificance. Such category assignments are made largely on the basis of expert proment of mutations to pathogenic status is often made on a
probabilistic basis, and not necessarily as a definitive binary
(“yes” [positive] or “no” [negative]) test result. Certainly, the
expectation threshold may have been set too high for genotyp-
ing initially, given the relatively few definitive scenarios that
emerge in HCM, with the pathogenicity of sequence variants
often difficult to establish with certainty. This principle is often
difficult to merge with clinical practice decision making, and
CM Mutation*icity of an HCM Mutation*
Potential Limitations for Interpretation
tives Often impractical
Family size may be small/relatives unavailable
Family compliance unpredictable
Requires resources for imaging/DNA studies in 3 relatives
(other than proband) including 1 with HCM phenotype†
causing
e
Absence of established comprehensive, curated, and cooperative
database tabulating mutations‡
High rate of novel (de novo; “private”) mutations in 65% of
probands
Interpretation of pathogenicity can be inconsistent among
testing laboratories
utation
ibly
Often insufficient size§
Control subjects should be unrelated, ethnicity-specific and free
of the disease in question
Potentially pathogenic variants can occur in subjects judged
clinically normal
Many rare benign (missense) variants in normals, termed
“background noise”
lly Inferred from evidence obtained from in nonhuman sources¶
, although meeting any 1 of the criteria can be sufficient to assign pathogenicity. †In clinical family
w gene in a research setting requiring linkage analysis over 3 generations with LOD (logarithm of
search laboratories include MutaDATABASE and Clin-Var; currently each clinical laboratory has
s of up to 400 subjects are in use. Includes: 1) Frameshift with profoundly altered amino acid
g in amino acids otherwise highly conserved through evolution in humans and across species; 3)
utated mouse or rabbit models of HCM; 2) in vitro basic metabolic cell culture assay experiments
h of each for clinical practice, and independent of the frequency with which
ng laboratories in formatting reports, to express the probability of pathogenicity.
nts of uncertain significance (VUS) are single nucleotide variants the significance
e of a mutation (in proband), is considered indeterminate, and of no clinical sig-
al judgment by clinical laboratory geneticists using currently available data.an Hogen
in rela
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August 21, 2012:705–15 Genetics in Hypertrophic Cardiomyopathytranslating complex molecular science to patient care has
proved more challenging than initially anticipated.
In addition, not generally recognized by clinicians is the
possibility that pathogenic classifications of variants can
change over time as new relevant information becomes
accessible (e.g., a VUS can be reassigned to pathogenic [or
alternatively, mutations regarded as disease-causing may be
downgraded], scenarios that could be considered a second
“Achilles heel” of genetic testing). Responsibility for noti-
fication of such reassignments to physicians and patients has
unavoidably been assumed by genetic testing laboratories.
However, the optimal strategies for this process are unclear
and standard procedures have not been established to
resolve these unique circumstances.
Clinical Applications of Genetic Testing
Mutation-specific screening of family members for HCM.
A common question asked by cardiologists is “Should my
HCM patient have genetic testing?” and it reflects the
persistent confusion regarding molecular strategies in this
disease (Figs. 3 and 4). Some form of family screening for HCM
s universally recommended (26), with the preferred first option
sually clinical testing with cardiac imaging and electrocardiogra-
hy to identify phenotype-positive relatives (27) (Table 4).
Screening of family members is also the predominant role
or genetic testing (i.e., to identify those at risk for devel-
ping disease who do not have LV hypertrophy) (26). This
trategy is initiated by successfully genotyping the proband
ith clinically expressed HCM. Failure to identify the
ausative mutation in the proband is an indeterminate result
hat provides no useful information and precludes predictive
esting in family members. It should be underscored that the
ikelihood of obtaining a positive test in the proband is only
bout 50%, as all genes causing HCM have not yet been
dentified, and are absent from testing panels (19,20,26)
Fig. 5). Furthermore, many of the detected mutations will
ot be judged pathogenic, thereby eliminating substantially
50% of families from the option of genotyping for
dentification of relatives at risk for HCM. Therefore, in only
minority of HCM probands will the result of the genetic test
e actionable for family screening.
If a pathogenic mutation is identified in a proband, it
ecomes a tool for screening at-risk relatives, with several
ossible diagnostic scenarios (26) (Figs. 3 and 4). In the
ost robust application of genetic testing, relatives testing
egative for the known family mutation are considered
naffected. This result largely alleviates the psychological and
conomic burden of further cardiovascular surveillance, imag-
ng tests or lifestyle and competitive sports restrictions (28).
However, extraordinarily rare (but possible) scenarios can
mpact the use of genetic testing to definitively exclude the risk
f developing HCM and make it imprudent to permanently
orgo imaging tests: 1) reassignment of a mutation from
ikely pathogenic to VUS; 2) proband with 1 disease-
ausing mutation in fact has a second mutation (unknown lnd undetected), which is transmitted to an offspring;
) laboratory or human error in processing/reporting a
utation; and 4) de novo mutation, not accounted for in
nitial proband testing, occurs in subsequent generations.
enotype positive-phenotype negative. Penetration of ge-
etic testing into clinical practice has created an important
egacy, evident as a new and rapidly expanding patient subset
ithin the HCM spectrum, i.e., genetically affected family
embers (usually MYH7 or MYBPC3 mutations) without
VH (29), although often with other markers such as
yocardial crypts or scarring, elongated mitral leaflets, or
iastolic dysfunction (11,30 –32) (Figs. 3 and 4). Such
ndividuals have generated clinical decision-making di-
Figure 3 Predictive Cascade (Generational) Testing
(A) A 45-year-old proband with a pathogenic MYH7 mutation. Genetic testing
provided 3 diagnostic scenarios in third-generation offspring: age 10 years,
unaffected status is virtually certain by absence of the mutation (reassuring to
the family given multiple HCM-SCDs); age 14 years, gene positive but pheno-
type negative is at risk for developing disease, requiring continued clinical sur-
veillance and imaging; age 22 years, diagnosis in patient with phenotypically
expressed HCM (but only mild LVH) is confirmed. (B) A 33-year-old mother with
clinical HCM diagnosis (probable pathogenic MYBPC mutation); 3 offspring
tested negative for that mutation, with risk to develop HCM virtually excluded.
Circles  females, squares  males; plus sign  present, zero  absent;
solid symbols  clinical HCM diagnosis; and slash  deceased. CMR  car-
diovascular magnetic resonance; HCM  hypertrophic cardiomyopathy; LVH 
left ventricular hypertrophy; SCD  sudden cardiac death.emmas: which (if any) should be disqualified from
t
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ered for prophylactic implantable cardioverter-
defibrillator therapy (28,29)?
While Bethesda Conference #36 consensus recommen-
dations do not exclude genotype positive-phenotype nega-
tive (G P) from sports (28), the paucity of evidence that
he nonhypertrophied LV is in fact electrically unstable (33)
an make clinical decisions difficult (29). Given the rela-
ively short period of time that genetic testing has been
vailable, the precise proportion of the G P population
hat will develop overt disease expression remains uncertain,
lthough believed to be low. Until rigorous penetrance data
re available, it is prudent to extend standard HCM
urveillance with cardiac imaging at least through midlife to
etect development of the phenotype.
On the basis of mutated HCM mouse and rabbit models,
here is emerging interest in drug strategies (antioxidants,
alcium-channel blockers, statins) to prevent development
f the phenotype and disease progression in G P
ndividuals (34,35). While there are no data that support
his hypothesis, studies are in progress assessing pharmaco-
Figure 4 Genetic Family Screening Strategies in HCM
*First option for assessment of family members would be a clinical screening eva
those relatives with negative or indeterminate clinical testing (for the HCM phenot
with coexisting conditions (e.g., systemic hypertension or physiologic athlete’s hea
tical obstacles including limited family size or patient compliance. ECG  electroc
genetic diagnosis; VUS  variant of uncertain significance; other abbreviations asogic prevention strategies in patients.Suspected HCM phenocopies. An application of genetic
testing is a disease-specific diagnosis in patients with LVH,
due to mutations in genes distinct from those that encode
sarcomere proteins. Metabolic myocardial storage cardio-
myopathies, often misdiagnosed clinically, comprise an
important but small fraction of patients genotyped for
suspicion of HCM (1%): regulatory subunit of adenosine
monophosphate-activated protein kinase (PRKAG2) glyco-
gen storage disease; lysosme-associated membrane protein
(LAMP2; Danon disease), an X-linked dominant lyosomal
storage disorder; Fabry, an X-linked recessive disease due to
mutations in the galactosidase alpha (GLA) gene, and
-galactosidase A deficiency leading to multiorgan intracel-
lular glycosphingolipid deposition (36–40).
Diagnostic distinction between sarcomeric HCM and its
phenocopies is crucial, given differences in natural history
and management strategies. For example, mutations in
LAMP2 are usually associated with rapid and potentially
lethal clinical course within the first 3 decades, requiring
early consideration for heart transplant (37,38). In Fabry
disease, clinical benefits have been attributed to enzyme
with imaging tests and ECG; the option of genetic testing is triggered largely for
Genetic testing may potentially lead to definitive diagnosis of HCM in patients
enetic screening often not productive; cosegregation, while an option, has prac-
raphy; ICD  implantable cardioverter-defibrillator; PGD  pre-implantation
re 3.luation
ype). †
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function and exercise capacity (39,40).
Clinical suspicion sufficient to trigger genetic testing can be
raised by: Wolff-Parkinson-White pattern in PRKAG2 and
LAMP2, or greatly increased precordial voltages and massive
LVH in patients with LAMP2 mutations (36–38). Fabry
isease can be suspected by symmetric LVH and late gadolin-
um enhancement in the posterobasal LV (39,40) (Fig. 6).
enotype–phenotype relationships/differential diagnosis.
positive genetic test in phenotypically expressed HCM is
nly confirmatory, but often useful when morphologic features
re mild, equivocal, or atypical. Genetic testing can potentially
esolve ambiguous clinical diagnoses such as HCM versus
thlete’s heart or systemic hypertension; however, in this
etting anticipated mutational yield is very low, and a negative
est is indeterminate and does not exclude HCM (26).
Availability of genetic testing has defined and expanded
he HCM clinical spectrum showing a variety of sarcomere
utations to be responsible for diverse disease expressions
nd new patient subgroups (Fig. 7). Patterns of LVH vary
reatly in closely related individuals (41) with phenotypes as
issimilar as apical aneurysms, end-stage, and massive or
nusual patterns of hypertrophy, including wall thickening
onfined to the apex, are all part of this heterogeneous
enetic disease (3,4,6,31,32,42,43). These observations dis-
el the notion that HCM is many similar but unrelated
onditions, and create the unifying principle of a single but
eterogeneous disease of the sarcomere.
redicting Prognosis With Mutations
ingle mutations. The early period of HCM genetics was
haracterized by substantial optimism and, in retrospect, the
nrealistic expectation that the discipline of molecular genetics
ould lead to a new paradigm in predicting the outcome of
Proposed Clinical Family Screening Strategies WithEchocar iography or Cardiovascular M gneticRes n nce (and 12-Lead Electrocardiogr phy) forD te tion f HCM With Left V ntricular Hyp rtr phy*†
Table 4
Proposed Clinical Family Screening Strategies With
Echocardiography or Cardiovascular Magnetic
Resonance (and 12-Lead Electrocardiography) for
Detection of HCM With Left Ventricular Hypertrophy*†
Age 12 yrs
Optional unless:
Malignant family history of premature death from HCM, or other adverse
complications
Competitive athlete in an intense training program
Onset of symptoms
Other clinical suspicion of early left ventricular hypertrophy
Age 12–21 yrs‡
Every 12–18 months
Age 21 yrs
Imaging at onset of symptoms, or possibly at 5-year intervals at least through
midlife; more frequent intervals for imaging are appropriate in families
with malignant clinical course, or history of late-onset HCM
*In family members who had not undergone genetic testing, or in whom testing was unresolved or
indeterminate. †Modified from Maron et al. (27). ‡Age range takes into consideration individual
variability in achieving physical maturity, and in some patients may justify screening at an earlier
age; initial evaluation should occur no later than early pubescence.
HCM  hypertrophic cardiomyopathy.ndividual patients (5,12). Early notions that specific missenseutations are linked to prognosis (5,10,11) have been unreal-
zed, in part by initial underappreciation of HCM as an
xceedingly complex biological entity with vast genetic heter-
geneity (11,15,21). While in the past some HCM genes and
ariants have been judged to convey more severe disease
onsequences than others (5,10–12,44,45), there is now con-
ensus on the basis of studies in large cohorts of unrelated
atients that routine screening for specific mutations (each
xceedingly uncommon in a genotyped population) cannot be
esignated either “benign” or “malignant” or reliably predict
linical outcome (17,18,21,26,46,47) (Fig. 4). Indeed, risk
tratification with conventional clinical markers (e.g.,
istory-taking or echocardiography) has served HCM well
s a more rigorous prediction model for identifying high-
isk patients who benefit from implantable cardioverter-
efibrillator therapy (48).
ultiple mutations. Through large-scale gene sequencing,
ata have emerged in HCM suggesting that double (or triple) or
ompound pathogenic mutations can be associated with more
evere disease expression and adverse prognosis (e.g., advanced
eart failure or sudden death, even in the absence of conventional
isk markers [49–51]) (Fig. 8). While it is possible that multiple
utations will prove to be prognostic markers or arbitrators of
mbiguous risk profiles, current evidence is preliminary and
rospective long-term studies in large populations are required.
Figure 5 Prevalence of HCM Genes in Probands
Distribution of genes encoding proteins of cardiac sarcomere in hypertrophic
cardiomyopathy (HCM) probands who undergo clinical genetic testing. A variety
of laboratories report a wide range in mutational yield (24% to 63%), leaving a
significant proportion of the HCM population genotype negative. Highest yields
are in HCM probands with multiple affected family members, while lower rates
are expected in probands without other affected family members (19,20).
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Assisted reproduction. Pre-implantation genetic diagnosis
allows couples with an increased risk for transmitting a severe
or potentially lethal genetic disease the opportunity to conceive
a child who will not inherit the pathogenic mutation (52) (Fig. 4).
After in vitro fertilization of harvested ova, a single cell is
removed from each embryo (8 cells; 3-day stage) and tested
for the specific mutation; only embryos free of the mutation
are transferred into the uterus.
Gene therapy. There is no established role for widespread
experimental genetic engineering in HCM, a disease often
associated with normal longevity. Gene therapy is also most
applicable to recessively inherited defects caused by muta-
tions associated with decreased or absent enzyme function.
Genetic Counseling
All HCM patients and relatives should be fully informed by
virtue of some form of genetic counseling. Those who
undergo genetic testing should receive specific pre- and
post-test counseling, including discussion of risks, benefits,
and options available (26,53). Certified genetic counselors
play an important role by collecting detailed family history
data to facilitate cosegregation studies and clarifying the
pathogenicity of mutations, as well as discussing family
Figure 6 Genetic Diagnosis of Sarcomeric HCM Phenocopies
(A) LAMP2 (Tyr109Ter mutation, resulting in truncated protein) in 12-year-old boy
1,425 g). (B) Histopathology showing marked scarring (stained blue) containing cl
sions are granular degraded lysosome material (Maron et al. [37], with permission
with LAMP2 (IVS6-2A-G splice site mutation), showing marked LV cavity dilatation
(Maron et al. [38], with permission of Elsevier). (D and E) CMR from 57-year-old w
wall (of left ventricle); HCM  hypertrophic cardiomyopathy; LA  left atrium; LV planning, and mitigating the psychosocial impact of inher-iting a potentially deleterious disorder (53). While the
multidisciplinary approach has considerable merit in bring-
ing together diverse expertise into 1 program (e.g., cardiol-
ogist, counselor, nurse), in the United States many HCM
patients are evaluated outside of academic hospital settings,
often making this model difficult to follow. As a conse-
quence, cardiologists and nursing staffs assume a greater role
in genetic counseling. In addition, all testing vendors have
clinical geneticists available for post-test consultation.
Legal Implications
Some patients are hesitant to contemplate genetic analysis
for a variety of reasons, most often confidentiality concerns.
However, in the United States, there is legislative protection
from genetic discriminatory practices. Since 2008, Genetic
Information Non-Discrimination Act (GINA) (54) has
been a federal law for which most employers and health
insurance providers are prohibited from denying or termi-
nating insurance, employment, or promotion based solely
on a mutation or family history of genetic disease. GINA
does not protect against discrimination in the military, for
life, disability, or long-term care insurance, or when there is
a documented medical condition. GINA is a major advan-
ed suddenly with massive hypertrophy (septal thickness 65 mm, heart weight
of distorted myocytes with distinctive vacuolated sarcoplasm (arrows); inclu-
American Medical Association). (C) Explanted heart from 24-year-old woman
ll thinning due to diffuse transmural and subepicardial scarring (white areas)
with Fabry disease and typical modest/symmetric LVH. Ao  aorta; FW  free
entricle; RV  right ventricle; VS  ventricular septum.who di
usters
of the
and wa
oman
left vtage in promoting the dissemination of genetic testing.
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The science underlying HCM genotyping has become exceed-
Figure 7 Utility of Genotyping for Defining Diverse
HCM Phenotypes Within the Clinical Spectrum
(A) LV apical aneurysms (arrowheads) with mid cavity muscular obstruction
(Maron et al. [32], with permission of the American Heart Association); (B) “end-
stage” remodeling with enlargement of LV (and atria) and wall thinning, associated
with systolic dysfunction; (C) massive hypertrophy (wall thickness 34 mm) in
anterolateral LV free wall (ALFW) (Maron et al. [42], with permission of Elsevier).
(D to F) Morphologic abnormalities in absence of LVH: (D) primary elongation of
anterior mitral leaflet (arrows) (Maron et al. [31], with permission of the American
Heart Association); (E) multiple LV myocardial crypts (arrows); (F) late gadolinium
enhancement indicative of replacement myocardial fibrosis (arrows). (G and G1)
De novo phenotypic conversion at advanced age: (G) LVH absent at age 46 years;
(G1) apical HCM (*) evident at age 51 years (Maron et al. [43], with permission of
Elsevier). D  distal cavity; P  proximal cavity; other abbreviations as in Figure 6.ingly complex, given the interfacing of a highly heterogeneousgenetic disease with an increasing appreciation for the funda-
mentally complex nature of normal human genetic variability
(i.e., with about 4 million largely benign nucleotide variants
unique to each person). Nevertheless, novel and rapidly evolv-
ing strategies for generating genetic data, using next-
generation technology, have emerged that will allow exome
and whole-genome sequencing, leading to even greater
amounts of genetic information. This opens up the possibility
of defining new genes responsible for HCM (55), but also a
multitude of novel variants and VUS for which clinical rele-
vance is uncertain.
Therefore, the application of genomics to HCM stands at a
crossroads. If genetic testing is to evolve and have a more
substantial role in the management of patients with HCM,
future efforts should focus on clarifying pathogenicity more
precisely for the substantial number of novel variants presently
recognized and those that will inevitably be identified by new
molecular techniques.
Consequently, it is timely to create clinically advantageous
collaborations among the commercial and academic testing
laboratories to promote the exchange of genetic information
and development of standardized mutational classification
schemes that can be more easily translated into patient care.
Databases that have been proposed for systematic assembly of
genetic data from clinical laboratories include MutaDATA-
BASE and Clin-Var. Such an initiative would almost certainly
improve the quality of genetic test reports by reducing ambi-
guity in terminology and interpretation.
Current genetic testing reports, which are both the window
to this science and a potential guide to patient care, often seem
too nuanced for the expectations of clinical cardiovascular
medicine. As a result, clinical decisions are sometimes made in
the context of rapidly evolving but often imprecise science,
underscoring the role of clinical correlation and judgment for
integrating diagnostic genetic testing into patient care.
Another transforming question is, given the complex and
probabilistic nature of genetic testing and the imperfect state of
knowledge, how (or by whom) should the results and impli-
cations of genetic testing be adjudicated? Should this respon-
sibility be confined to those elite (“master”) clinical geneticists
harboring a higher level of expertise? (15). Perhaps, more
realistically, genetic test reports could be modeled with more
clinically relevant language so that patient-specific interpreta-
tions do not require special knowledge or teaching.
Conclusions
Closing this communication gap currently separating clini-
cians from basic scientists is paramount. To this purpose it
would be important to work toward greater standardization
and less ambiguity in reporting mutations, hopefully en-
abling such testing to achieve the confidence of the clinical
community and ultimately its full potential for translating
basic genetic information into HCM decision making and
patient management.
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